Screening for Glaucoma: U.S. Preventive Services Task Force Recommendation Statement.

Annals of internal medicine (Impact Factor: 17.81). 07/2013; 159(7). DOI: 10.7326/0003-4819-159-6-201309170-00685
Source: PubMed


Update of the 2004 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for glaucoma.
The USPSTF reviewed evidence on the benefits and harms of screening for glaucoma and of medical and surgical treatment of early glaucoma. Beneficial outcomes of interest included improved vision-related quality of life and reduced progression of early asymptomatic glaucoma to vision-related impairment. The USPSTF also considered evidence on the accuracy of glaucoma screening tests.
This recommendation applies to adults who do not have vision symptoms and are seen in a primary care setting.
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for primary open-angle glaucoma in adults. (I statement).

0 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Previously, the patient-reported Total Illness Burden Index for Prostate Cancer (TIBI-CaP) questionnaire and/or the physician-reported Charlson Comorbidity Index (CCI) have provided assessments of competing comorbidity during treatment decisions for patients with prostate cancer. In the current study, the authors used these assessments to determine comorbidity and prognosis before prostate biopsy and the subsequent diagnosis of prostate cancer to identify those patients least likely to benefit from treatment. Methods: A prospective observational cohort study was performed of 104 participants aged 64.0 years ± 6.5 years from 3 institutions representing different health care delivery systems. Patients were identified before undergoing transrectal ultrasound-guided prostate biopsy and followed for a median of 28 months. Associations between the comorbidity scores and nonelective hospital admissions were investigated using logistic regression and Cox proportional hazards models. Results: Among the 104 patients who underwent prostate biopsy, 2 died during the follow-up period. The overall hospital admission rate was 20% (21 of 104 patients). Higher scores on both the TIBI-CaP (≥ 9) and CCI (≥ 3) were found to be significantly associated with an increased odds for hospital admission (odds ratio, 11.3 [95% confidence interval (95% CI), 2.4-53.6] and OR, 5.7 [95% CI, 1.4-22.4]) and hazards ratios (HRs) for time to hospital admission (HR, 3.8 [95% CI, 1.3-11.2] and HR, 3.2 [95% CI, 1.1-9.1]), respectively. Conclusions: TIBI-CaP and CCI scores were found to successfully predict which patients were at high risk for nonelective hospital admission. These patients are likely to have poorer health and a potentially shortened lifespan. Therefore, comorbidity analysis using these tools may help to identify those patients who are least likely to benefit from prostate cancer therapy and should avoid prostate biopsy.
    Cancer 07/2013; 119(13). DOI:10.1002/cncr.28044 · 4.89 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Transplant recipients have elevated cancer risk including risk of human papillomavirus (HPV)-associated cancers of the cervix, anus, penis, vagina, vulva and oropharynx. We examined the incidence of HPV-related cancers in 187 649 US recipients in the Transplant Cancer Match Study. Standardized incidence ratios (SIRs) compared incidence rates to the general population, and incidence rate ratios (IRRs) compared rates across transplant subgroups. We observed elevated incidence of HPV-related cancers (SIRs: in situ 3.3-20.3, invasive 2.2-7.3), except for invasive cervical cancer (SIR 1.0). Incidence increased with time since transplant for vulvar, anal and penile cancers (IRRs 2.1-4.6 for 5+ vs. <2 years). Immunophenotype, characterized by decreased incidence with HLA DRB1:13 and increased incidence with B:44, contributed to susceptibility at several sites. Use of specific immunosuppressive medications was variably associated with incidence; for example, tacrolimus, was associated with reduced incidence for some anogenital cancers (IRRs 0.4-0.7) but increased incidence of oropharyngeal cancer (IRR 2.1). Thus, specific features associated with recipient characteristics, transplanted organs and medications are associated with incidence of HPV-related cancers after transplant. The absence of increased incidence of invasive cervical cancer highlights the success of cervical screening in this population and suggests a need for screening for other HPV-related cancers.
    American Journal of Transplantation 10/2013; 13(12). DOI:10.1111/ajt.12472 · 5.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Asia Pacific region accounts for more than 50% of global blindness. Although most attention has appropriately been focused on cataract, the most prevalent and treatable cause of global blindness, other conditions including glaucoma contribute significantly to visual impairment. The population attributable risk percentage for glaucoma suggests that it is a significant public health problem, and generally, case detection rather than population-based screening is the most appropriate strategy to identify disease. Glaucoma management requires the full range of comprehensive ophthalmic examination skills and therefore allows the diagnosis of most other potentially blinding conditions as well: these skills should be part of residency training in all developing countries in the region. A comprehensive examination on all patients presenting to an eye clinic not only detects glaucoma but also provides the opportunity to expand existing cataract-centered programs toward the larger goal of prevention of blindness from any cause. Local efforts to improve residency training can be supplemented by regional support such as assistance in curriculum development and assessment of trainees. Assistance in glaucoma training would involve in-country diagnostic and surgical training with extended stays to teach postoperative care, supplemented by possible fellowships in developed countries. Although these changes will not have a large impact on blindness from glaucoma in the short term, they have the potential to develop a framework and skill set that is required for long-term reduction in morbidity from blindness of all causes, including glaucoma.
    01/2014; 3(1):4-8. DOI:10.1097/APO.0000000000000024
Show more

Similar Publications